Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
Dr. Hung will provide an overview of Medivation and its clinicaldevelopment programs for Dimebon for Alzheimer's and Huntington's diseases andMDV3100 for prostate cancer.
A live audio webcast will be available on the "Events and Presentations"page of the "Investor Relations" section of the Company's website athttp://www.medivation.com. A replay also will be available for 30 daysfollowing the live presentation.
Medivation, Inc. is a biopharmaceutical company focused on the rapiddevelopment of novel small molecule drugs to treat serious diseases for whichthere are limited treatment options. Medivation aims to transform thetreatment of these diseases and offer hope to critically ill patients andtheir caregivers. In September 2008, Medivation entered into a globalagreement with Pfizer Inc to develop and commercialize Dimebon for thetreatment of Alzheimer's and Huntington's diseases. With Pfizer, the Companyis conducting a broad Dimebon clinical development program, including apivotal and confirmatory Phase 3 trial, known as the CONNECTION study, inpatients with mild-to-moderate Alzheimer's disease. The program also includesadditional trials planned to begin this year in Alzheimer's disease, as wellas further development of Dimebon in patients with mild-to-moderateHuntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 inpatients with castration-resistant (also known as hormone-refractory) prostatecancer is ongoing. For more information, please visit us athttp://www.medivation.com.
SOURCE Medivation, Inc.
You May Also Like